By far the majority of the excitatory and inhibitory neurotransmission processes in the central nervous system are mediated by, respectively, L-glutamate and y-aminobutyrate (GABA), which at the same time serve roles as constituents of cellular intermediary metabolism (Schousboe, 198 I). Therefore, a discussion of the metabolism of these amino acid neurotransmitters should distinguish between the neurotransmitter pools and the metabolically related pools of glutamate and GABA. Since this mini-review concerns primarily the neurotransmitter role of glutamate and GABA, only the biochemistry of the transmitter-related pools will be discussed. Since the neurotransmission process involves not only biosynthesis and metabolism but also evoked release, receptor interaction as well as inactivation via high-affinity cellular uptake, each of these processes will be discussed below.
Biosynthesis of neurotransmitter glutamate and G A BA
The biosynthetic route of neurotransmitter GABA is generally agreed to consist of a decarboxylation of glutamate to GABA catalysed by glutamate decarboxylase (GAD). It has, however, been suggested (Yoneda et al., 1982) that the ornithine 8-aminotransferase (Om-T) catalysed conversion of ornithine via glutamic semialdehyde to GABA might also have a regulatory role in the synthesis of GABA. The recent finding that only GABA neurons appear to express Om-T with a low K , for ornithine seems to favour this notion. Table 1 gives the actual activities of these enzymes in GABA-ergic neurons, glutamatergic neurons and astrocytes, and it is seen that G A D is only present in neurons utilizing GABA as their neurotransmitter while Om-T is present with equal activity in all three cell types. This underlines the key role for G A D in GABA synthesis (Roberts, 1979) .
In contrast to the clarity concerning the biosynthetic pathway for neurotransmitter GABA, it is not at all clear how neurotransmitter glutamate is synthesized. Results of studies where neurotransmitter glutamate was labelled from different precursors in vivo as well as in isolated preparations of brain slices or cells (Bradford et al., 1978 (Bradford et al., , 1983 Hamberger et al., 1979) , together with studies of the cellular Abbreviations used: GABA, y-arninobutyrate; GAD, glutamate decarboxylase; Om-T. ornithine 6-aminotransferase; AAT, aspartate amhotransferase; GLDH, glutamate dehydrogenase; PAG, phosphateactivated glutaminase; NMDA, N-methyl-maspartate Vol. 15 distribution of enzymes involved in glutamate metabolism (Hertz et af., 1983) , have, however, indicated that the most likely biosynthetic pathways for neurotransmitter glutamate are those catalysed by any one of the enzymes, aspartate aminotransferase (AAT), glutamate dehydrogenase (GLDH) and phosphase-activated glutaminase (PAG). As seen from Table, I , these enzymes are present in glutamatergic neurons but it should be noted that, with the exception of AAT, the activities determined in either GABA-ergic neurons or astrocytes are comparable with those observed in glutamatergic neurons. The conspicuously high activity of AAT in these neurons (Drejer et al., 1985a) together with the immunocytochemical localization of AAT in brain areas with known glutamatergic activity (Altshuler et al., 1981; Wenthold & Altschuler, 1983) may be indicative of a special role for this enzyme in glutamatergic neurons. The exact nature of this role has yet to be elucidated.
Release processes for glutamate and GA BA
Using a variety of techniques such as intracerebral microdialysis or superfusion of tissue slices, cells or subcellular fractions, it has been possibly to study evoked release of glutamate and GABA both from different brain areas in vivo Lehmann et al., 1983; Benveniste et a[., 1984; Sandberg et al., 1986) and from isolated neurons (Drejer et al., , 19856, 1986 Gallo et al., 1982; Larsson et al., 1983a; Yu et a[., 1984~) or synaptosomes (Hertz, 1979) . Such studies have provided important information about the influence of different pathological conditions on release of amino acid neurotransmitters (Bosley (Potashner, 1979; Johnston et al., 1980; Mitchell, 1980; Levi & Gallo, 1981; Meier et al., 1984; Schousboe et al., 19856; Drejer et al., 1986) . Primary cultures of neurons from the central nervous system have recently been successfully used as model systems to study effects of a variety of neurotransmitters and pharmacological agents on evoked release of glutamate (aspartate) and GABA. (Table 2) . It is, moreover, seen from Table 2 that the transmitter release from cerebellar granule cells can be inhibited either by low-affinity GABA, receptors or by adenosine-A, receptors (J. Drejer & A. Schousboe, unpublished work) .
Receptors f o r glutamate and GABA Glutamate receptors have for some time, based on pharmacological evidence, been classified into three major classes, namely the quisqualate-, NMDA-and kainate-sensitive receptors (Watkins & Evans, 1981) . Recently, a fourth subtype of glutamate receptors which is sensitive to the phosphonic acid derivative L-aminophosphonobutyric acid has been reported (Fagg et al., 1982) and as shown in Table 2 cerebellar granule cells express a glutamate receptor which does not recognize any of these glutamate analogues but only L-glutamate and L-aspartate (Drejer et al., 1986) . Since glutamate receptors are thought to be mediators of seizure activity (Meldrum & Chapman, 1983; Frandsen et al., 1986) as well as glutamate neurotoxicity (Olney, 1978) there is a growing interest in the pharmacology of these receptors. In particular, there is a need for potent and selective glutamate receptor subtype antagonists of which those that are presently known (e.g. phosphonic acids of aminovaleric, aminohexanoic and aminoheptanoic acid, glutamic acid diethylester and y-D-glutamylglycine) are not sufficiently potent and specific.
In terms of pharmacological subtypes, GABA receptors appear less complex than glutamate receptors, since only two subclasses of GABA receptors have been described so far. These are normally referred to as bicuculline-sensitive GABA, and baclofen-sensitive but bicuculline-insensitive GABA, receptors (Hill & Bowery, 1981) . GABA, receptors are, however, composed of high-and low-affinity subtypes (Wang et al., 1979; , the function of which has not been adequately worked out at the present time. It has, however, been proposed that the higher-affinity GABA, receptors mediate the neurotrophic activity of GABA (Hansen et al., 1984; Meier et al., 1985; Schousboe et al., 19856; Belhage et al., 1986) and the low-affinity GABA receptors have been shown to mediate the inhibitory action of GABA on evoked glutamate release from cerebellar granule cells (Meier et a[., 1984) .
Inactivation and metabolism of glutamate and GABA
The termination of the neurotransmitter action of both glutamate and GABA appears to be brought about by highaffinity uptake into both presynaptic nerve endings and astroglial cells (Hertz, 1979; Schousboe, 1981 Schousboe, , 1982 Hosli et al., 1986) . The importance of the astrocytic uptake relative to that into neurons seems to be different for the two amino acids. In case of glutamate the astrocytic uptake is unquestionably quantitatively superior to that into neurons Schousboe et al., 1983a , whereas in case of GABA, neuronal uptake is quantitatively more important than the uptake into astrocytes .
The substrate specificities for the transport carriers of glutamate and GABA have been studied extensively (for refs. see Schousboe, 1982; Schousboe et al., 1983~1, 1987 . In the case of glutamate only small differences between neuronal and astrocytic uptake seem to exist. D-Aspartate is a linear competitive inhibitor of L-glutamate and L-aspartate uptake into neurons but it has been shown to interact in a somewhat complex manner with the L-glutamate uptake into astrocytes . Otherwise, a variety of glutamate analogues appear to have very similar effects on neuronal and astrocytic glutamate uptake Balcar et al., 1987) . Contrary to glutamate uptake, neuronal and glial GABA uptake exhibit distinctly different properties (Schousboe et al., 1978 (Schousboe et al., , 1979a (Schousboe et al., , 1983a Larsson et al., 1981 . Moreover, GABA analogues which preferentially inhibit glial GABA uptake have been shown to act as anticonvulsants (Krogsgaard-Larsen et al., 198 1 ; Croucher et al., 1983; Schousboe et al., 19836, 1986~; Wood et al., 1983) apparently via an increase in the synaptic GABA pool (Wood et al., 1980; . In contrast, GABA analogues which selectively inhibit neuronal GABA uptake are proconvulsants (Meldrum et al., 1982) . One of the first compounds, which was suggested to preferentially inhibit glial GABA uptake and which has been extensively used as a marker for glial GABA uptake in brain slices in vivo, is fl-alanine (Iversen & Kelly, 1975; Schon & Kelly, 1975). In a recent study (Larsson et al., 19866) where a mutual inhibition kinetic analysis of 8-alanine, GABA and taurine uptake into neurons and astrocytes was performed it was, however, shown that /3-alanine is not transported by the GABA carrier but utilizes the taurine carrier in both neurons and glial cells (Table 3) . Therefore, /3-alanine can not be used as a marker for glial GABA uptake. The metabolism of glutamate in neurons and astrocytes appears to differ somewhat, depending on the cell type. In both GABA-ergic neurons and astrocytes exogenously supplied glutamate is to a considerable extent metabolized to CO, via a concerted action of GLDH and a-ketoglutarate dehydrogenase (Yu et af., 1982, 1984a,b) . In glutamatergic neurons, however, this process occurs only to a very small extent (Schousboe et al., 19851) . In astrocytes, which in contrast to neurons express glutamine synthetase (Norenberg & Martinez-Hernandez, 1979) , glutamate is also metabolized to glutamine (Yu el al., 1982 (Yu el al., , 1984a Waniewski & Martin, 1986 ), which appears to be released from the astrocytes (Waniewski & Martin, 1986) .
In both neurons and astrocytes GABA is metabolized via GABA-transaminase (Schousboe. 1981) . Anticonvulsant compounds such as valproate and y-vinyl GABA have been shown to inhibit preferentially the neuronal GABAtransaminase (Larsson et al., 1986a) but the mechanism for this is not fully understood. Neurons appear, however, to be superior to astrocytes with regard to high-affinity uptake of y-vinyl GABA .
Glutamate and glutamine are key amino acids in mammalian intermediary metabolism, intimately associated with aerobic metabolism via the tricarboxylic acid cycle, with ammonia metabolism and also involved in the synthetic pathways of numerous biologically important compounds (Meister, 1979) . Research in various aspects of the metabolism and function of these amino acids has been continuous since the earliest days of modern biochemical studies.
The direction of these studies has traced a path through the traditional biochemical methodologies and now encompasses other powerful techniques such as immunohistochemistry and molecular biology.
What has become apparent from these multidisciplinary studies on different organ systems is a pattern of greater complexity and heterogeneity than previous work might have suggested. There is not only the expected intracellular and interorgan diversity, but intercellular heterogeneity is becoming a more commonly accepted phenomenon, even in organs Abbreviations used: GABA, 4-aminobutyrate; DON, 6-diazo-5-0x0-L-norleucine. such as the liver (Gebhardt & Mecke, 1983; Haussinger, 1983; Sies & Haussinger, 1984) . Nowhere is this complexity and heterogeneity more apparent, nor more intensely studied, than in the nervous system (for reviews, Balazs & Cremer, 1973; Bradford, 1982; Hertz er al., 1983) . In the central nervous system, glutamate and its decarboxylation product, 4-aminobutyrate (GABA), may well function as important neurotransmitter substances. Thus superimposed on the 'normal' role of glutamate and glutamine in cellular metabolism with its accompanying transport systems and enzymes is the further complication of specific membrane-associated receptor proteins and the associated ion-channel systems. In addition, glutamate and related neuroexcitatory substances are also potentially neurotoxic. The pharmacological and toxicological consequences of multiple receptor types for excitatory dicarboxylic amino acids are only now being understood and exploited (Olney, 1983; Meldrum, 1985) . It is clear from this that exquisite regulatory mechanisms must be present to separate these various functions of ubiquitously distributed amino acids such as glutamate and glutamine. The homoeostatic regulation of the neuroactive amino acids is associated with a heterogeneity of enzyme distribution amongst the neurons and glial cells that make up the nervous system (Nicklas, 1983~) . Most current evidence would suggest that transmitter pools of glutamate are formed in glutamergic synaptic endings from glutamine via the activity of phosphateactivated glutaminase (EC 3.5.1.2), which catalyses the hydrolytic cleavage of glutamine to glutamate and ammonia.
